Effect of bezuclastinib on the pathobiology of mastocytosis: changes in bone marrow mast cells, tryptase, and KIT p.D816V variant allele frequency from the pivotal SUMMIT trial
NCODA Oncology and Hematology Meeting Abstracts · 2026
DOI: 10.67209/cucn1340 ↗Kurz gefasst
Fachartikel in der Zeitschrift NCODA Oncology and Hematology Meeting Abstracts, 2026. Verfasst von Tract George und 12 weiteren Autor:innen. Die Arbeit nennt 5 Literaturangaben.
Abstract (Originalsprache)
Background
Systemic mastocytosis (SM) includes a spectrum of subtypes characterized by variable degrees of neoplastic mast cell (MC) infiltration of tissues. The gain-offunction KIT p.D816V mutation drives SM in ~95% of patients. Most patients have nonadvanced SM (NonAdvSM). Pathological and molecular markers of disease burden, including degree of bone marrow (BM) MC infiltration, serum tryptase (ST) elevation, and KIT p.D816V variant allele frequency (VAF) detection, determine NonAdvSM subtype, indicate disease severity, and correspond to progression and survival risk. Bezuclastinib is an oral, potent, and selective type 1 tyrosine kinase inhibitor with activity against KIT D816V.3 The SUMMIT trial evaluated bezuclastinib in NonAdvSM. Here, we describe bezuclastinib’s effects on ST, KIT p.D816V VAF, and BM MCs in SUMMIT Part 2.
Objectives
Explain the therapeutic hypothesis of bezuclastinib, an oral, potent, and selective type 1 tyrosine kinase inhibitor, in nonadvanced systemic mastocytosis. Evaluate the pathological and molecular biomarker data of bezuclastinib from the pivotal SUMMIT trial in patients with nonadvanced systemic mastocytosis and recognize how therapeutic targeting of the underlying disease mechanism may improve patient outcomes. Understand the relevance of correlating subjective and objective measures of disease burden with emerging targeted therapies such as bezuclastinib.
Methods
SUMMIT evaluated bezuclastinib in NonAdvSM patients with inadequate symptom control despite best supportive care (BSC) medications. Patients were randomized 2:1 to 100mg every day (QD) bezuclastinib+BSC or placebo+ BSC. Primary endpoint was 24-week mean change from baseline in Mastocytosis Symptom Severity Daily Diary (MS2D2) total symptom score (TSS) (range 0–110). Key secondary endpoints included the proportion of patients with ≥50% reduction in ST, KIT p.D816V VAF, BM MC burden, MS2D2 TSS, and ≥30% TSS reduction. ST, KIT p.D816V VAF, and BM biopsy were obtained at baseline and week 24 to determine the effect of bezuclastinib vs placebo on pathologic measures of disease. MC aggregation, morphology, and immunophenotype were assessed. Immunohistochemical staining for CD117, tryptase, CD25, CD30, and CD34 were performed on BM sections.
Results
179 patients enrolled in SUMMIT Part 2: n=119 bezuclastinib, n=60 placebo; median age (range) 51 (23- 78) years; 65.9% female; mean (range) baseline MS2D2 TSS 55.6 (13-105). Median (range) baseline blood KIT p.D816V VAF was 0.25% (0-34%); 77.7% of patients had detectable KIT p.D816V at baseline. Median (range) baseline BM MC burden was 10% (1-75%); 75% had MC aggregates at baseline. Median (range) baseline ST was 40 (6-692) ng/ mL; ST was ≥20 ng/mL in 82.1%. Reduction in ST by >50% was achieved in 87.4% of patients receiving bezuclastinib vs 0% receiving placebo after 24 weeks (p
Zitieren
APA
George, T., Boggs, N., Patel, J., Ret, A., Moser, K., Menon, M., Pilla, A., Zhang, J., Sun, L., Singh, P., Soomro, R., Easton, R., & Rein, L. (2026). Effect of bezuclastinib on the pathobiology of mastocytosis: changes in bone marrow mast cells, tryptase, and KIT p.D816V variant allele frequency from the pivotal SUMMIT trial. NCODA Oncology and Hematology Meeting Abstracts. https://doi.org/10.67209/cucn1340
Vancouver
George T, Boggs N, Patel J, Ret A, Moser K, Menon M, et al. Effect of bezuclastinib on the pathobiology of mastocytosis: changes in bone marrow mast cells, tryptase, and KIT p.D816V variant allele frequency from the pivotal SUMMIT trial. NCODA Oncology and Hematology Meeting Abstracts. 2026. doi:10.67209/cucn1340
BibTeX
@article{George2026,
author = {George, Tract and Boggs, Nathan and Patel, Jay and Ret, Anton and Moser, Karen and Menon, Madhu and Pilla, Amanda and Zhang, Jenna and Sun, Lei and Singh, Priya and Soomro, Raheela and Easton, Rachael and Rein, Lindsay},
title = {Effect of bezuclastinib on the pathobiology of mastocytosis: changes in bone marrow mast cells, tryptase, and KIT p.D816V variant allele frequency from the pivotal SUMMIT trial},
journal = {NCODA Oncology and Hematology Meeting Abstracts},
year = {2026},
doi = {10.67209/cucn1340}
}
EUVIMED